First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity

Vaccine

Volumn 33, Issue 23, 2015, Pages 2690-2696

  Schijns, Virgil E J C ^a,b,c   Pretto, Chrystel ^b,c   Devillers, Laurent ^b,c   Pierre, Denis ^b,c   Hofman, Florence M ^d   Chen, Thomas C ^d,e   Mespouille, Pascal ^f   Hantos, Peter ^g   Glorieux, Philippe ^f   Bota, Daniela A ^h   Stathopoulos, Apostolos ^{a,b,c,d,e,g,h}  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b Epitopoietics Research Corporation (ERC)   (Belgium)

^c Epitopoietic Research Corporation (ERC)   (Netherlands)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e Epitopoietic Research Corporation   (United States)

^f Dept of Neurosurgery   (Belgium)

^g NONE   (Belgium)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Allogeneic; Autologous; Glioma; Immunotherapy; Vaccine

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CYCLOPHOSPHAMIDE; GLIOVAC; SARGRAMOSTIM; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; ERYTHEMA; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VIVO STUDY; LOCAL SKIN REACTION; LOW DRUG DOSE; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; RAT; REGULATORY T LYMPHOCYTE; REOPERATION; SKIN INDURATION; SKIN ULCER; TREATMENT DURATION; TREATMENT RESPONSE; ULCER; ACTIVE IMMUNIZATION; ADVERSE EFFECTS; ANIMAL; MIDDLE AGED; PROCEDURES; RECURRENT DISEASE; TREATMENT OUTCOME; UNITED STATES; VACCINATION;

ADULT; AGED; ANIMALS; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; MIDDLE AGED; PRECISION MEDICINE; RATS; RECURRENCE; TREATMENT OUTCOME; UNITED STATES; VACCINATION;

EID: 84929044807     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.095     Document Type: Article

References (33)

1. Yang I., Tihan T., Han S.J., Wrensch M.R., Wiencke J., Sughrue M.E., et al. CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci 2010, 17(11):1381-1385.
2. Schneider J., Hofman F.M., Apuzzo M.L., Hinton D.R. Cytokines and immunoregulatory molecules in malignant glial neoplasms. J Neurosurg 1992, 7(2):265-273.
3. Bowles A.P., Perkins E. Long-term remission of malignant brain tumors after intracranial infection. A report of four cases. Neurosurgery 1999, 44(3):636-642.
4. Fecci P.E., Mitchell D.A., Whitesides J.F., Xie W., Friedman A.H., Archer G.E., et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006, 66(6):3294-3302.
5. Weir G.M., Liwski R.S., Mansour M. Immune modulation by chemotherapy to enhance cancer vaccines. Cancers 2011, 3:3114-3142.
6. Fadul C.E., Fisher J.L., Gui J., Hampton T.H., Côté A.L., Ernstoff M.S. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro-Oncolology 2011, 13(4):393-400.
7. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996.
8. Park J.K., Hodges T., Arko L., Shen M., Dello Iacono D., McNabb A., et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 2010, 28(24):3838-3843.
9. Chamberlain M.C. Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol 2011, 5:117-129.
10. Schijns V.E., Lavelle E.C. Trends in vaccine adjuvants. Expert Rev Vaccines 2011, 10(4):539-550.
11. Chang D.Z., Lomazow W., Joy Somberg C., Stan R., Perales M.A. Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. Hematology 2004, 9(3):207-215.
12. Min L., Mohammad Isa S.A., Shuai W., Piang C.B., Nih F.W., Kotaka M., et al. Cutting edge: granulocyte-macrophage colony-stimulating factor is the major CD8+ T cell-derived licensing factor for dendritic cell activation. J Immunol 2010, 184(9):4625-4629.
13. Schuler G., Schuler-Thurner B., Steinman R.M. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003, 15:138-147.
14. Daenen L.G., Shaked Y., Man S., Xu P., Voest E.E., Hoffman R.M., et al. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent anti-tumor activity in preclinical human tumor xenograft. Models Mol Cancer Ther 2009, 8(10):2872-2881.
15. Gidudu J., Kohl K.S., Halperin S., Hammer S.J., Heath P.T., Hennig R., et al. A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2008, 26:6800-6813.
16. Khasraw M., Holodny A., Goldlust S.A., DeAngelis L.M. Intracranial hemorrhage in patients with cancer treated with bevacizumab: the memorial Sloan-Kettering experience. Ann Oncol 2012, 23(2):458-463.
17. Wen P.Y., Macdonald D.R., Reardon D.A., Cloughesy T.F., Sorensen A.G., Galanis E., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010, 28(11):1963-1972.
18. Barker F.G., Chang S.M., Gutin P.H., Malec M.K., McDermott M.W., Prados M.D., et al. Neurosurgery 1998, 42:709-720.
19. Stummer W., Reulen H.-J., Meinel T., Pichlmeier U., Schumacher W., Tonn J.C., et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008, 62:564-576.
20. Bota D.A., Alexandru-Abrams D., Pretto C., Hofman F.M., Chen T.C., Fu B., et al. Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report. Perm J. 2015 Mar 1, [Epub ahead of print]. 10.7812/TPP/14-042.
21. Chamberlain M.C., Johnston S.K. Salvage therapy with single agent benvacizumab for recurrent glioblastoma. J Neurooncol 2010, 105(3):523-530.
22. Rozados V.R., Mainetti L.E., Rico M.J., Zacarías Fluck M.F., Matar P., Scharovsky O.G. The immune response and the therapeutic effect of metronomic chemotherapy with cyclophosphamide. Oncol Res 2010, 18(11-12):601-605.
23. Disis M.L., Bernhard H., Shiota F.M., Hand S.L., Gralow J.R., Huseby E.S., et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996, 88(1):202-210.
24. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 2002, 188:147-154.
25. Armitage J.O. The use of granulocyte-macrophage colony-stimulating factor in bone marrow transplantation. Semin Hematol 1992, 29(4 Suppl 3):14-18.
26. Kaplan G., Walsh G., Guido L.S., Meyn P., Burkhardt R.A., Abalos R.M., et al. Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med 1992, 175(6):1717-1728.
27. Herrlinger U., Aulwurm S., Strik H., Weit S., Naumann U., Weller M. MIP-1alpha antagonizes the effect of a GM-CSF-enhanced subcutaneous vaccine in a mouse glioma model. J Neurooncol 2004, 66(1-2):147-154.
28. Soiffer R., Lynch T., Mihm M., Jung K., Rhuda C., Schmollinger J.C., et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 1998, 95(22):13141-13146.
29. Ghulam Muhammad A.K., Candolfi M., King G.D., Yagiz K., Foulad D., Mineharu Y., et al. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res 2009, 15(19):6113-6127.
30. Barcia C., Gómez A., Gallego-Sanchez J.M., Perez-Vallés A., Castro M., Lowenstein P.R., et al. Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells. Am J Pathol 2009, 175(2):786-798.
31. Berd D., Sato T., Maguire H.C., Kairys J., Mastrangelo M.J. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004, 22(3):403-415.
32. Hsueh E.C., Morton D.L. Antigen-based immunotherapy of melanoma: canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol 2003, 13(6):401-407.
33. Sosman J.A., Sondak V.K. Melacine: an allogeneic melanoma tumor cell lysate vaccine. Expert Rev Vaccines 2003, 2(3):353-368.